1
|
Gandellini P, Doldi V and Zaffaroni N:
microRNAs as players and signals in the metastatic cascade:
Implications for the development of novel anti-metastatic
therapies. Semin Cancer Biol. 44:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Trevisani F, Ghidini M, Larcher A, Lampis
A, Lote H, Manunta P, Alibrandi MT, Zagato L, Citterio L,
Dell'Antonio G, et al: MicroRNA 193b-3p as a predictive biomarker
of chronic kidney disease in patients undergoing radical
nephrectomy for renal cell carcinoma. Br J Cancer. 115:1343–1350.
2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zhao L, Zhu J, Zhou H, Zhao Z, Zou Z, Liu
X, Lin X, Zhang X, Deng X, Wang R, et al: Identification of
cellular microRNA-136 as a dual regulator of RIG-I-mediated innate
immunity that antagonizes H5N1 IAV replication in A549 cells. Sci
Rep. 5:149912015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Teixeira AL, Dias F, Gomes M, Fernandes M
and Medeiros R: Circulating biomarkers in renal cell carcinoma: The
link between microRNAs and extracellular vesicles, where are we
now? J Kidney Cancer VHL. 1:84–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhou J, Yun EJ, Chen W, Ding Y, Wu K, Wang
B, Ding C, Hernandez E, Santoyo J, Pong RC, et al: Targeting
3-phosphoinositide-dependent protein kinase 1 associated with
drug-resistant renal cell carcinoma using new oridonin analogs.
Cell Death Dis. 8:e27012017. View Article : Google Scholar : PubMed/NCBI
|
7
|
Haas NB, Manola J, Uzzo RG, Flaherty KT,
Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, et al:
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic
renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind,
placebo-controlled, randomised, phase 3 trial. Lancet.
387:2008–2016. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Visone R and Croce CM: MiRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Voinnet O: Origin, biogenesis, and
activity of plant microRNAs. Cell. 136:669–687. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Mikhaylova O, Stratton Y, Hall D, Kellner
E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J, et
al: VHL-regulated MiR-204 suppresses tumor growth through
inhibition of LC3B-mediated autophagy in renal clear cell
carcinoma. Cancer Cell. 21:532–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Liu H, Brannon AR, Reddy AR, Alexe G,
Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: With
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Aguiari G: MicroRNAs in clear cell renal
cell carcinoma: Biological functions and applications. J Kidney
Cancer VHL. 2:140–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Motzer RJ, Figlin RA, Martini JF,
Hariharan S, Agarwal N, Li CX, Williams JA and Hutson TE: Germline
genetic biomarkers of sunitinib efficacy in advanced renal cell
carcinoma: Results from the RENAL EFFECT trial. Clin Genitourin
Cancer. 15:526–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
15
|
Liu F, Chen N, Xiao R, Wang W and Pan Z:
miR-144-3p serves as a tumor suppressor for renal cell carcinoma
and inhibits its invasion and metastasis by targeting MAP3K8.
Biochem Biophys Res Commun. 480:87–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen G, Shen ZL, Wang L, Lv CY, Huang XE
and Zhou RP: Hsa-miR-181a-5p expression and effects on cell
proliferation in gastric cancer. Asian Pac J Cancer Prev.
14:3871–3875. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wu S, Gu Y, Huang Y, Wong TC, Ding H, Liu
T, Zhang Y and Zhang X: Novel biomarkers for non-functioning
invasive pituitary adenomas were identified by using analysis of
micrornas expression profile. Biochem Genet. 55:253–267. 2017.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Korhan P, Erdal E and Atabey N:
MiR-181a-5p is downregulated in hepatocellular carcinoma and
suppresses motility, invasion and branching-morphogenesis by
directly targeting c-Met. Biochem Biophys Res Commun.
450:1304–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Adams BD, Parsons C, Walker L, Zhang WC
and Slack FJ: Targeting noncoding RNAs in disease. J Clin Invest.
127:761–771. 2017. View
Article : Google Scholar : PubMed/NCBI
|
21
|
Eichmüller SB, Osen W, Mandelboim O and
Seliger B: Immune modulatory micrornas involved in tumor attack and
tumor immune escape. J Natl Cancer Inst. 109:2017. View Article : Google Scholar
|
22
|
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu
XY, Yu ZW, Jia YH, Bai XF, Li L, et al: The lncRNA CRNDE promotes
colorectal cancer cell proliferation and chemoresistance via
miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol
Cancer. 16:92017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Li Y, Kuscu C, Banach A, Zhang Q,
Pulkoski-Gross A, Kim D, Liu J, Roth E, Li E, Shroyer KR, et al:
miR-181a-5p inhibits cancer cell migration and angiogenesis via
downregulation of matrix metalloproteinase-14. Cancer Res.
75:2674–2685. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ma Z, Qiu X, Wang D, Li Y, Zhang B, Yuan
T, Wei J, Zhao B, Zhao X, Lou J, et al: MiR-181a-5p inhibits cell
proliferation and migration by targeting Kras in non-small cell
lung cancer A549 cells. Acta Biochim Biophys Sin (Shanghai).
47:630–638. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Mi Y, Zhang D, Jiang W, Weng J, Zhou C,
Huang K, Tang H, Yu Y, Liu X, Cui W, et al: miR-181a-5p promotes
the progression of gastric cancer via RASSF6-mediated MAPK
signalling activation. Cancer Lett. 389:11–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Liu K, Xie F, Gao A, Zhang R, Zhang L,
Xiao Z, Hu Q, Huang W, Huang Q, Lin B, et al: SOX2 regulates
multiple malignant processes of breast cancer development through
the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 16:622017.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Petrillo M, Zannoni GF, Beltrame L,
Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L,
Vizzielli G, Scambia G, et al: Identification of high-grade serous
ovarian cancer miRNA species associated with survival and drug
response in patients receiving neo-adjuvant chemotherapy: A
retrospective longitudinal analysis using matched tumor biopsies.
Ann Oncol. 27:625–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
28
|
Boguslawska J, Sokol E, Rybicka B, Czubaty
A, Rodzik K and Piekielko-Witkowska A: microRNAs target SRSF7
splicing factor to modulate the expression of osteopontin splice
variants in renal cancer cells. Gene. 595:142–149. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zaravinos A, Pieri M, Mourmouras N,
Anastasiadou N, Zouvani I, Delakas D and Deltas C: Altered
metabolic pathways in clear cell renal cell carcinoma: A
meta-analysis and validation study focused on the deregulated genes
and their associated networks. Oncoscience. 1:117–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
31
|
de Araújo Júnior RF, Oliveira Leitão AL,
de Melo Silveira RF, de Oliveira Rocha HA, de França Cavalcanti P
and de Araújo AA: Telmisartan induces apoptosis and regulates Bcl-2
in human renal cancer cells. Exp Biol Med (Maywood). 240:34–44.
2015. View Article : Google Scholar : PubMed/NCBI
|